Introduction {#S1}
============

The third most common type of cancer is colorectal cancer (CRC), which is also ranked as the second most frequent cause of cancer-related death worldwide ([@B4]). In 2018, more than 1.8 million patients are diagnosed with CRC where at least 881,000 of them die of the complications brought upon by the disease ([@B4]). The pathogenesis of CRC involves multiple factors, including genetic and environmental factors ([@B19]). Colorectal cancer remains a global health concern because it is highly prevalent, and its prognosis remains poor despite the rapid emergence of tools for diagnosis and treatments ([@B5]; [@B23]). As a result, it is imperative to improve the diagnostic approach, prognostic prediction, and survival outcomes by identifying novel therapeutic targets in CRC.

Medical literature has highlighted the important and active roles of different types of RNAs in the cancer's progression and development ([@B22]; [@B39]). In the human genome sequence, more than 90% could be transcribed but could not code for proteins ([@B40]). The majority of the transcriptome is accounted for by non-coding RNAs or ncRNAs. Continuous discovery has emerged on the different regulative RNA classes with vital biological functions ([@B2]). Non-coding RNAs of more than 200 bp are classified as the long non-coding RNAs (lncRNAs) ([@B32]). Recent research highlights the key functions of lncRNAs in the regulation of biological processes. These include genomic imprinting, immune response, cell cycle and apoptosis, immune response, and different types of cancer ([@B3]; [@B12]). In CRC, lncRNAs have been known with the possibility to suppress tumors or function as oncogenes ([@B9]). Current research indicates the function of lncRNAs as miRNA sponges and competing endogenous RNAs (ceRNAs). This reduces the availability of miRNAs for mRNA target binding ([@B29]; [@B34]). The ceRNA hypothesis underlines the interaction of the RNA with miRNA response elements (MREs). This type of crosstalk and competition in the RNA also occurs among mRNAs and lncRNAs ([@B49]). Further research is recommended on lncRNAs' function as ceRNAs. Additionally, studies with larger sample sizes should be conducted on CRC's association with lncRNA-mediated ceRNA network in a whole-genome sequence.

Nomogram is a statistical prediction model that combines multiple prognostic factors to make intuitive graphical and individualized predictions ([@B16]). Up to date, various kinds of prognostic models were reported in CRC ([@B35]; [@B41]; [@B52]). Although doubts about the predictive value of clinicopathological features are increasing, they still provide the most reliable guidelines for the prognostication and treatment of CRC ([@B50]). Thus, we deduced that integrating genomic signatures with clinicopathological features in a model would yield a predictive accuracy exceeding that of the currently available prognostic system. Here, we aimed to apply a systematic approach to evaluate the clinical usefulness of CRC-related signatures and then construct a composite clinicopathologic--genomic nomogram by integrating factors with potential prognostic value based on TCGA database.

Materials and Methods {#S2}
=====================

Data Collection {#S2.SS1}
---------------

We generated data on CRC from TCGA. Through the GDC apps, we downloaded the gene expression data of the mRNAseq (level 3) through the Data Transfer Tool. Also, we downloaded the clinical information of CRC patients and the samples of miRNAseq^[1](#footnote1){ref-type="fn"}^. To achieve an accurate and completely annotated lncRNA and mRNA datasets, we compared the level 3 mRNAseq gene expression data with the annotation information of the Ensembl Genome Browser 99(GRCh38.p13) database^[2](#footnote2){ref-type="fn"}^ ([@B7]). The data used in this study met the following criteria: (a) CRC patients with complete information on age, gender, tumor location, tumor recurrence, neoplasm cancer, residual tumor, tumor stage, T stage, N stage, and M stage; (b) patients with complete lncRNAseq, mRNAseq, and miRNAseq data. Finally, 335 CRC samples and 51 normal control samples were collected in our study. Our research meets the publication guidelines provided by TCGA^[3](#footnote3){ref-type="fn"}^.

Differentially Expressed Analysis {#S2.SS2}
---------------------------------

We applied the "edgeR" package in R to identify differentially expressed lncRNAs (DElncRNAs), miRNAs (DEmiRNAs), and mRNAs (DEmRNAs) between CRC and adjacent normal tissues ([@B28]). Thresholds for the screening of differentially expressed RNAs were adjusted *P* \< 0.05 and \|log~2~fold change (FC)\| \> 2.

Functional Annotation {#S2.SS3}
---------------------

We performed analyses on the functional and pathway enrichment of DEmRNAs with the use of a R package called "clusterprofiler" ([@B44]) that includes the pathway enrichment analyses of the Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@B20]) and the Gene Ontology (GO) ([@B1]). Statistical significance of functional categories, visualized using R, is set at a false discovery rate (FDR) of \< 0.05.

Construct the ceRNA Network {#S2.SS4}
---------------------------

We created a ceRNA network that was built on the hypotheses that the potential impact of lncRNAs on miRNAs is evident, and it could also carry out the behaviors of miRNA sponges for more enhanced regulation of mRNAs. The ENCORI forecasted the lncRNA--miRNA interactions^[4](#footnote4){ref-type="fn"}^. These interactions were founded on specific CRC miRNAs. Through miRDB^[5](#footnote5){ref-type="fn"}^, TargetScan^[6](#footnote6){ref-type="fn"}^, and miRTarBase^[7](#footnote7){ref-type="fn"}^, our team predicted the miRNA-targeted mRNAs. Only mRNAs recognized by all three databases were considered candidate targets and overlapping with the identified DEmRNAs to screen out the DEmRNAs that were targeted by the DEmiRNAs. A careful cross-matching was executed between the predicted results and the results of the DEmiRNAs, DElncRNAs, and DEmRNAs. We accessed the visual overview of the results through Cytoscape 3.7.0 (Cytoscape Consortium, San Diego, CA, United States) from these networks ([@B30]).

Survival Analysis {#S2.SS5}
-----------------

With the use of the survival package in R, we plotted the Kaplan--Meier curves of the lncRNAs, miRNAs, and mRNAs in the ceRNA network along with the combination of the CRC patients' clinical data in TCGA. The optimal cutoff values for RNA expression were determined by X-tile software (version 3.6.1; Yale University, New Haven, CT, United States) ([@B6]). Using univariate Cox regression, the associations between overall survival (OS) and the lncRNAs, miRNAs, and mRNAs in the ceRNA network were assessed. Genes with a *P* \< 0.05 in the univariate Cox regression analysis were included into the stepwise multivariate Cox regression analysis. The inclusion of these values generated a formula of the risk score. Ultimately, utilizing the median of the risk scores of lncRNA, miRNA, and mRNA as the threshold, we classified the risk into high and low to group the patients accordingly. We assessed the variations in OS among the patients who are grouped as low and high risk through the log-rank tests and Kaplan--Meier survival plots. Additionally, we adopted the analysis of the receiver operating characteristic (ROC) curve, along with the area under the ROC curve (AUC) to evaluate the survival prediction.

Construction of Nomogram {#S2.SS6}
------------------------

There were 335 patients included in the nomogram, and the whole enrolled cohort was considered as the primary cohort. Fifty percent, 70%, and 90% of patients from the primary cohort were randomly selected as validation sets. An assessment was conducted on the associations of relevant clinical features and ceRNAs risk score with OS using Cox proportional hazards regression models. For the multivariable Cox proportional hazards regression models, variables were identified using both the Akaike Information Criterion (AIC) and the concordance index (C-index). To predict the probability of 1-, 3-, and 5-year OS, selected variables were incorporated in the nomogram using the statistical software, known as the rms in R, version 3.0.3 ([@B37]). Two indicators, namely the decision curve analysis (DCA) and the calibration curve, measured its predictive performance. The designs and details of the lncRNA--miRNA--mRNA ceRNA network analysis are displayed in the flowchart of [Figure 1](#F1){ref-type="fig"}. Using the SPSS 21.0 statistical package (IBM Corporation, Armonk, NY, United States) and R project version 3.5.1^[8](#footnote8){ref-type="fn"}^ for Windows, we performed all the statistical analyses and random allocation. Finally, we set the *P* \< 0.05 to determine the statistical significance of the difference.

![The flowchart of the designs and details of the lncRNA--miRNA--mRNA ceRNA network analysis.](fgene-11-00583-g001){#F1}

Results {#S3}
=======

Identifying DElncRNAs, DEmiRNAs, and DEmRNAs {#S3.SS1}
--------------------------------------------

Expression data of RNAs and miRNAs were collected from 386 specimens, which were composed of 335 CRC samples and 51 normal samples. After the RNAseq data were mapped to the human reference genome, we obtained a total of 14,080 lncRNAs, 1,881 miRNAs, and 19,600 mRNAs. By comparing the CRC group with the normal group, we identified the significant DElncRNAs, DEmiRNAs, and DEmRNAs using the edgeR package in R software. As a result, 830 DElncRNAs, 289 DEmiRNAs, and 2,086 DEmRNAs were confirmed by the edgeR package in R software. Of these, we inferred 529 upregulated DElncRNAs and 301 downregulated differential lncRNAs, 208 upregulated differential miRNAs and 81 downregulated miRNAs, and 1,041 upregulated differential mRNAs and 1,045 downregulated differential mRNAs, respectively ([Figure 2](#F2){ref-type="fig"}).

![Volcano plot of differentially expressed lncRNAs (DElncRNAs), differentially expressed miRNAs (DEmiRNAs), and differentially expressed mRNAs (DEmRNAs) in colorectal cancer (CRC) and non-tumorous adjacent-normal samples. **(A)** Volcano plot of differentially expressed lncRNAs (DElncRNAs). **(B)** Volcano plot of differentially expressed miRNAs (DEmiRNAs). **(C)** Volcano plot of differentially expressed mRNAs (DEmRNAs). Log~2~fold change (log~2~FC) \> 2 was labeled in red; log~2~FC \< -2 was in green (*P* \< 0.01).](fgene-11-00583-g002){#F2}

Functional Annotation {#S3.SS2}
---------------------

We analyzed these mRNAs using the R software package clusterprofiler to identify the functions linked to the DEmRNAs. This evaluation revealed the enrichment of 921 GO terms along with 55 KEGG pathways (FDR \< 0.05). We chose to show the top 20 GO terms and 20 KEGG pathways of the DEmRNAs based on the gene count ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). Biological processes of GO analyses were suggested to focus on muscle contraction (GO:0006936) and muscle system process (GO:0003012). The cellular component process found that the target genes are mainly clustered into the apical plasma membrane (GO:0016324) and apical part of cell (GO:0045177). Regarding the molecular functions process, the target genes are significantly related to receptor ligand activity (GO:0048018) and receptor regulator activity (GO:0030545). The KEGG pathways showed significant enrichment of the following pathways, such as neuroactive ligand--receptor interaction (hsa04080), drug metabolism--cytochrome P450 (hsa00982), salivary secretion (hsa04970), and cAMP signaling pathway (hsa04024).

![Gene ontology and KEGG pathway functional enrichment analyses of the differentially expressed mRNAs (DEmRNAs). **(A)** The biological function category of GO classification. **(B)** The cell component category of GO classification. **(C)** The molecular function category of GO classification. **(D)** KEGG pathway functional classification and annotation.](fgene-11-00583-g003){#F3}

Construction of a ceRNA Network {#S3.SS3}
-------------------------------

The construction of a ceRNA network graph that is built on these data provides comprehensive information on how lncRNA mediates mRNA through the combination of miRNA in CRC. Cytoscape v 3.7.0 provides a visual overview ([Figure 4](#F4){ref-type="fig"}). We investigated the interactions between the DEmiRNAs and the DElncRNAs based on ENCORI, and 661 interactions between the DEmiRNAs and the DElncRNAs were predicted, which include 161 lncRNAs and 97 miRNAs. Next, the miRNA--mRNA target regulation network was further assessed using TargetScan, miRDB, and miRTarBase. Moving forward, these 97 miRNAs were found to interact with the 161 of the DEmRNAs. Ultimately, we selected 161 DElncRNAs, 97 DEmiRNAs, and 161 DEmRNAs for the construction of the ceRNA network ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}).

![The lncRNA--miRNA--mRNA ceRNA network in colorectal cancer (CRC). **(A)** A global view of the ceRNA network in CRC. **(B--I)** hsa-mir-20a, hsa-mir-126, hsa-mir-144, hsa-mir-186, hsa-mir-301a, hsa-mir-376b, hsa-mir-526b, and hsa-mir-3942 mediated lncRNA-mRNA ceRNA network.](fgene-11-00583-g004){#F4}

Survival Analysis for the ceRNAs {#S3.SS4}
--------------------------------

The univariate Cox regression identified the significant prognostic value of 14 lncRNAs ([Supplementary Table S3](#TS3){ref-type="supplementary-material"}), 11 miRNAs ([Supplementary Table S4](#TS4){ref-type="supplementary-material"}), and seven mRNAs ([Supplementary Table S5](#TS5){ref-type="supplementary-material"}) in the ceRNA network. Using a stepwise multivariate Cox proportional hazards regression analysis, we indicated that nine-lncRNA (AC103740.1, AC069120.1, CASC11, AC016027.1, ST8SIA6-AS1, AL109615.3, H19, MIR17HG, and TSPEAR-AS2) signatures, eight-miRNA (hsa-mir-20a, hsa-mir-376b, hsa-mir-526b, hsa-mir-126, hsa-mir-301a, hsa-mir-186, hsa-mir-3942, and hsa-mir-144) signatures, and five-mRNA (HIF3A, SPTBN2, DACH1, EREG, and FOXG1) signatures showed a significant prognostic value for CRC. [Figure 5](#F5){ref-type="fig"} presents the risk scores and survival status of patients' distribution in these three ceRNAs. The risk score model attained the AUC values of 0.739, 0.736, and 0.674 from the nine-lncRNA, eight-miRNA, and five-mRNA signatures accordingly. More specifically, the positive correlation of low risk with OS (*P* \< 0.001, [Figure 6](#F6){ref-type="fig"}) was confirmed by the Kaplan--Meier curves of these three signatures.

![Risk score analysis of the nine-lncRNA, eight-miRNA, and five-mRNA signatures of CRC. **(A)** Risk score analysis, receiver operating characteristic (ROC) curve analysis, and risk heatmap of the nine-lncRNA signature expression profiles. **(B)** Risk score analysis, ROC curve analysis, and risk heatmap of the eight-miRNA signature expression profiles. **(C)** Risk score analysis, ROC curve analysis, and risk heatmap of the five-mRNA signature expression profiles.](fgene-11-00583-g005){#F5}

![Kaplan--Meier survival curves for the nine lncRNAs, eight miRNAs, and five mRNAs in the ceRNA network related to overall survival. **(A)** Kaplan--Meier survival curves for the nine lncRNAs. **(B)** Kaplan--Meier survival curves for the eight miRNAs. **(C)** Kaplan--Meier survival curves for the five mRNAs.](fgene-11-00583-g006){#F6}

To further clarify their expression and prognostic value, we performed Kaplan--Meier survival analysis for the lncRNAs, miRNAs, and mRNAs in these three RNA signatures in patients with CRC from TCGA ([Figure 7](#F7){ref-type="fig"}). The results showed that six lncRNAs (AC069120.1, AC103740.1, AL109615.3, H19, ST8SIA6-AS1, and TSPEAR-AS2), three mRNAs (FOXG1, HIF3A, and SPTBN2), and five miRNAs (hsa-mir-126, hsa-mir-186, hsa-mir-301a, hsa-mir-526b, and hsa-mir-3942) were identified as cancer-promoting factors because of their high expression correlation with shorter OS in patients with CRC. In contrast, another three lncRNAs (AC016027.1, CASC11, and MIR17HG), two mRNAs (DACH1, and EREG), and three miRNAs (hsa-mir-20a, hsa-mir-144, and hsa-mir-376b) showed high expression correlated with longer OS, implying that these RNAs might be protective factors in CRC.

![Kaplan--Meier survival curves for the nine-lncRNA, eight-miRNA, and five-mRNA signatures. **(A)** Kaplan--Meier survival curves for the nine-lncRNA signature. **(B)** Kaplan--Meier survival curves for the eight-miRNA signature. **(C)** Kaplan--Meier survival curves for the five-mRNA signature.](fgene-11-00583-g007){#F7}

Establishment and Internal Validation of the Nomogram {#S3.SS5}
-----------------------------------------------------

To establish the nomogram, we evaluated the prognostic value of distinct clinical features. [Table 1](#T1){ref-type="table"} demonstrates the correlation between eight of 13 evaluated clinical features and OS, which was verified through the univariate Cox proportional hazards regression. The independent prognostic indicators of CRC include the age, N stage, M stage, lncRNA risk score, and miRNA risk score. The smallest AIC value and highest C-index occurred when we incorporated five variables (age, tumor stage, lncRNA risk score, miRNA risk score, and mRNA risk score) into the multivariate Cox regression model for OS \[AIC = 462.82, C-index = 0.838 (95% CI, 0.785--0.891)\]. [Figure 8A](#F8){ref-type="fig"} illustrates how nomogram predicted the OS of the CRC patients in the TCGA database. We predicted the survival probabilities of the CRC patients in three different timelines, at 1, 3, and 5 years using the nomogram. [Figure 8B](#F8){ref-type="fig"} shows the calibration plot for the 3-year prediction of OS, which demonstrated a good overall prediction. For the estimation of OS risk, the nomogram displayed C-index of 0.822 (95% CI = 0.749--0.895), 0.845 (95% CI = 0.816--0.903), and 0.842 (95% CI = 0.787--0.897) in the 50, 70, and 90% validation cohort, respectively. As [Figure 8C](#F8){ref-type="fig"} illustrates, the nomogram demonstrated a better net benefit that had a wider range of threshold probability on the DCA for predicting the corresponding 1-, 3-, and 5-year OS. [Figure 8D](#F8){ref-type="fig"} represents how the DCA confirmed the higher net clinical benefit of the nomogram in contrast with the lncRNA risk score + miRNA risk score + mRNA risk score and age + tumor stage. This analysis took into account a wide selection of threshold probabilities that could predict the 3-year OS. Furthermore, at higher threshold probability levels, this is a representation of an exceptional estimation of decision outcomes.

###### 

Cox proportional hazards regression model showing the association of variables with overall survival.

  Variables                       Patient *N* = 335   Univariate analysis                   Multivariate analysis                              
  ------------------ ------------ ------------------- --------------------- --------------- ----------------------- ----------- -------------- ---------
  Age                ≤65          152                 Reference                                                     Reference                  
                     \>65         183                 1.815                 1.010--3.261    0.046                   1.944       1.074--3.518   0.028
  Gender             Male         162                 Reference                                                                                
                     Female       173                 1.013                 0.775--1.324    0.924                                              
  Tumor location     Right        147                 Reference                                                                                
                     Left         188                 0.967                 0.566--1.652    0.903                                              
  Tumor recurrence   No           261                 Reference                                                                                
                     Yes          74                  0.740                 0.348--1.572    0.434                                              
  Neoplasm cancer    Tumor free   153                 Reference                                                                                
                     With tumor   182                 0.924                 0.541--1.578    0.771                                              
  Residual tumor     R0           280                 Reference                                                                                
                     R1 + R2      55                  2.948                 1.693- 5.133    \<0.001                                            
  Tumor stage        I            58                  Reference                                                                                
                     II           125                 1.209                 0.331--4.410    0.774                                              
                     III          102                 3.149                 0.932--10.647   0.065                                              
                     IV           50                  7.806                 2.325--26.207   0.001                                              
  T stage            T1           12                  Reference                                                                                
                     T2           57                  0.644                 0.067--6.192    0.703                                              
                     T3           233                 1.827                 0.250--13.320   0.522                                              
                     T4           33                  4.379                 0.554--37.600   0.161                                              
  N stage            N0           188                 Reference                                                     Reference                  
                     N1           88                  2.498                 1.259--4.958    0.009                   2.771       1.331--5.766   0.006
                     N2           59                  4.923                 2.522--9.609    \<0.001                 4.116       1.960--8.643   \<0.001
  M stage            M0           285                 Reference                                                     Reference                  
                     M1           50                  4.178                 2.413--7.234    \<0.001                 3.280       1.791--6.005   \<0.001
  lncRNA risk        Low          168                 Reference                                                     Reference                  
                     High         167                 4.004                 2.100--7.633    \<0.001                 4.900       2.485--9.662   \<0.001
  miRNA risk         Low          168                 Reference                                                     Reference                  
                     High         167                 1.853                 1.370--2.506    \<0.001                 4.027       2.155--7.524   \<0.001
  mRNA risk          Low          168                 Reference                                                                                
                     High         167                 1.670                 1.239--2.251    0.001                                              

HR, hazard ratio; CI, confidence interval.

![Nomogram, calibration plots, and decision curve analysis for the prediction of overall survival (OS) in patients with CRC. **(A)** Nomogram predicting 1-, 3-, and 5-year OS for CRC patients. **(B)** Calibration plot for nomogram predicted and observed 3-year overall survival rate. **(C)** Decision curve analysis for 1-, 3-, and 5-year overall survival predictions. **(D)** Decision curve analysis comparing nomogram with the lncRNA risk score + miRNA risk score + mRNA risk score model and the age + tumor stage.](fgene-11-00583-g008){#F8}

To provide more plausible classifications of OS, patients were stratified into two groups that were based on an NTP's optimal cutoff value identified by the median. Based on [Figure 9A](#F9){ref-type="fig"}, the results suggest that patients from the high-risk group had significantly worse outcomes compared to the low-risk group (*P* \< 0.001). Using the cohorts for validation, we verified the same results, as demonstrated by [Figures 9B--D](#F9){ref-type="fig"}.

![Kaplan--Meier analysis according to nomogram total points (NTP). **(A)** Kaplan--Meier survival curves for the primary cohort. **(B)** Kaplan--Meier survival curves for the 50% validation cohort. **(C)** Kaplan--Meier survival curves for the 70% validation cohort. **(D)** Kaplan--Meier survival curves for the 90% validation cohort.](fgene-11-00583-g009){#F9}

Discussion {#S4}
==========

Globally, CRC is known for being one of the most frequently occurring malignancies, ranking second in women and third in men ([@B13]). Although great progress in the treatment, prognosis, and diagnosis of CRC, its mortality still remains high. The further study of efficient biomarkers and underlying mechanisms will drive the development of CRC diagnosis and treatment. We explored the CRC's pathogenic mechanism in our study and identified a new prognostic predictor model for it.

The interaction of different RNA transcripts through shared MREs has been introduced in recent years through what is known as the ceRNA hypothesis ([@B29]). Competitors that bind the common miRNA have been identified in many human ceRNAs in RNA regulatory networks ([@B8]; [@B34]). Using the TCGA database, we utilized a broad cohort in this study to identify DElncRNAs, DEmiRNAs, and DEmRNAs between tissues that are normal and are of CRC. Eventually, we obtained a cohesive view of the ceRNA regulatory crosstalk between the RNA transcripts of these CRC-specific through the construction of the lncRNA--miRNA--mRNA ceRNA network. Many studies have been focused on the roles of lncRNAs in cancer initiation and progression ([@B17]; [@B27]). In the ceRNA network, lncRNAs, miRNAs, and mRNAs are significantly linked to the CRC patients' survival and clinical features. This study analyzes the regulatory interaction between RNAs that are non-coding and protein-coding. The results attempt to primarily define the ceRNA-mediated molecular mechanism that operates in the colorectal tumorigenesis at the level of transcription.

In various cancers, the evident presence of dysregulated lncRNAs demonstrated an association with patient survival ([@B14]; [@B33]; [@B45]). Furthermore, the development of numerous lncRNA signatures improves the prognosis prediction of cancers that includes glioblastoma multiforme ([@B48]), breast cancer ([@B25]), and lung cancer ([@B51]). Recently, [@B38] and [@B10] identified lncRNA signatures to prognosis prediction of CRC using Cox regression analysis. According to the expression values of nine DElncRNAs in the ceRNA network of patients, we generated a risk score model. We also found that, based on varied expression profiles of patients, nine-lncRNA signature differentiates CRC patients between poor and good prognoses. The nine-lncRNA signature is as follows: AC103740.1, AC069120.1, CASC11, AC016027.1, ST8SIA6-AS1, AL109615.3, H19, MIR17HG, and TSPEAR-AS2. A potential prognostic lncRNA, known as the ST8SIA6-AS1 from the nine lncRNAs, is recommended to become a tumor progression indicator that is applicable in different types of cancers ([@B11]; [@B24]). In the context of CRC, our findings confirmed ST8SIA6-AS1's important role in CRC's progression and supported existing reports by presenting consistent results. Nevertheless, more experimental evidence is required to verify the role of ST8SIA6-AS1 in the development of CRC.

In the instances where the components of various RNA transcripts affect each other, the miRNAs presented their key roles as the hub elements of the ceRNA network. Mediated by hsa-mir-301a, CASC19, H19, HAGLR, HOTAIR, MIR17HG, and TMEM132D-AS1 interacted with CFL2, RBM20, and SALL3 in the present CRC-specific ceRNA network. Consistent with our results, hsa-mir-301a was demonstrated to be involved in the pathogenesis of CRC, and high expression of hsa-mir-301a indicated an unfavorable clinical outcome ([@B47], [@B46]). Hence, we combined eight miRNAs, namely hsa-mir-20a, hsa-mir-376b, hsa-mir-526b, hsa-mir-126, hsa-mir-301a, hsa-mir-186, hsa-mir-3942, and hsa-mir-144, to develop a risk score. From this, we deduced the independent prediction of OS by this eight-miRNA signature in CRC patients. From our understanding, our study is the first that combines a ceRNA network with TCGA data and constructs a miRNA-related risk score to evaluate the OS of CRC patients.

An association was also found between some mRNAs in the ceRNA network and the survival of CRC patients, which is similar to lncRNAs and miRNAs. These mRNAs are the protective mRNA, such as DACH1 and EREG, and the risky mRNA, such as FOXG1, HIF3A, and SPTBN2. In many studies, the DACH1 has been involved in the prognosis of CRC ([@B42]; [@B36]). More specifically, reports showed that loss of DACH1 expression results in increased CRC cell growth, motility, and invasiveness through transforming growth factor β-mediated Epithelial-Mesenchymal Transition (EMT), and downregulation of DACH1 has important therapeutic implications for targeted therapies of CRC ([@B36]). In our ceRNA network, DACH1 could interact with hsa-mir-217, and many lncRNAs such as HOTAIR, LINC01748, and MIR17HG could function as molecular sponge to regulate hsa-mir-217. However, these lncRNA--miRNA--mRNA novel potential interaction hypotheses require further investigation and experimental confirmation. The establishment of a five-mRNA signature-based prognostic prediction system based on the mRNAs in the ceRNA network includes HIF3A, SPTBN2, DACH1, EREG, and FOXG1. As presented by the results of the Kaplan--Meier survival analysis, this system classified patients in the TCGA dataset into good, bad, and significantly different prognoses. In a univariable Cox regression model, we found a significantly shorter OS for patients with high-risk scores. This directly corresponds to an increase in CRC-related deaths. Overall, these results suggest that, in molecular pathogenesis, progression, and the prognosis of CRC, these mRNAs could play a fundamental role.

As far as we know, this is the first nomogram to combine clinicopathological data with lncRNA, miRNA, and mRNA signatures. In predicting the OS of CRC patients, the sufficient clarity and adequate calibration of the nomogram's C-index were at 0.838. To further investigate the predictive ability of the nomogram, we reviewed some published nomograms for prognosis prediction in CRC, which were contained RNA signatures and clinical features ([@B18]; [@B41]; [@B15]; [@B21]; [@B26]; [@B31]; [@B43]). We found that the C-index of our nomogram was significantly greater than that of other nomograms. Additionally, our recently completed nomogram model had a significantly higher level of net benefit, as demonstrated by the DCA results.

Despite our nomogram's supportive role in the prediction of OS in CRC patients by the physicians, our research has several limitations. First, although the data of this study were all from the TCGA database, they were retrospective essentially, so a large-scale and multicenter prospective study should be launched to prove our results and eliminate the selective bias. Second, in our study, we used the mRNAseq, miRNAseq data, and clinicopathological data in the TCGA database to construct the nomogram. It is difficult to find a suitable similar dataset in other databases for external validation of this nomogram. However, the risk-prediction model presents optimal predictive power. Third, one final step still needs to be completed before clinical application. In large prospective trials, polymerase chain reaction--based validations would be of great significance in the clinical setting. Finally, to expound upon the inherent association between these RNA signatures and CRC prognosis, increase in experimental data on these RNAs is mandatory.

Conclusion {#S5}
==========

In conclusion, with the use of bioinformatics analysis, our study revealed the CRC-specific ceRNA network. Using the information from the TCGA database, we also investigated their associations with clinical features. Furthermore, our research specifies that tumorigenesis occurs through the dysregulation of ceRNA network. We established a nomogram based on gene expression profile, clinical features, and pathological factors for predicting OS in CRC patients. Ultimately, the excellent discrimination and risk stratification of the formulated nomogram obtain the prediction OS in CRC patients.
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